Protein kinase CK2 in hematologic malignancies: Reliance on a pivotal cell survival regulator by oncogenic signaling pathways

Leukemia

Volumn 26, Issue 6, 2012, Pages 1174-1179

  Piazza, F ^a,b   Manni, S ^a,b   Ruzzene, M ^a,b   Pinna, L A ^a,b   Gurrieri, C ^a,b   Semenzato, G ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

blood tumors; hematopoiesis; kinase inhibitors; protein kinase CK2

Indexed keywords

BETA CATENIN; CASEIN KINASE II; CX 4945; CYTOTOXIC AGENT; DASATINIB; I KAPPA B ALPHA; I KAPPA B BETA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH;

ANIMALS; CASEIN KINASE II; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 84862005662     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.385     Document Type: Review

References (60)

1. St-Denis NA, Litchfield DW. Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 2009; 66: 1817-1829.
2. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369 (Pt 1): 1-15. (Pubitemid 36174119)
3. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003; 17: 349-368. (Pubitemid 36292951)
4. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB et al. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cellautonomous defect and early embryonic lethality. Mol Cell Biol 2003; 23: 908-915. (Pubitemid 36133509)
5. Seldin DC, Lou DY, Toselli P, Landesman-Bollag E, Dominguez I. Gene targeting of CK2 catalytic subunits. Mol Cell Biochem 2008; 316: 141-147.
6. Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. Nat Genet 1999; 23: 118-121. (Pubitemid 29418801)
7. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010; 1804: 499-504.
8. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858-1867.
9. Gyenis L, Litchfield DW. The emerging CK2 interactome: insights into the regulation and functions of CK2. Mol Cell Biochem 2008; 316: 5-14.
10. Filhol O, Cochet C. Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair. Cell Mol Life Sci 2009; 66: 1830-1839.
11. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol 2001; 16: 573-582. (Pubitemid 32297655)
12. McNeill H, Woodgett JR. When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol 2010; 11: 404-413.
13. Staal FJ, Luis TC. Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions. J Cell Biochem 2010; 109: 844-849.
14. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 2005; 274: 63-67. (Pubitemid 41001501)
15. Song DH, Sussman DJ, Seldin DC. Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem 2000; 275: 23790-23797. (Pubitemid 30627458)
16. Wang S, Jones KA. CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol 2006; 16: 2239-2244. (Pubitemid 44739279)
17. Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E et al. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of betacatenin transcriptional activity. J Cell Physiol 2011; 226: 1953-1959.
18. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E et al. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem 2011; 356: 127-132.
19. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell 2008; 15: 801-812.
20. Mar BG, Amakye D, Aifantis I, Buonamici S. The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia 2011; 25: 1665-1673.
21. Jia H, Liu Y, Xia R, Tong C, Yue T, Jiang J et al. Casein kinase 2 promotes Hedgehog signaling by regulating both smoothened and Cubitus interruptus. J Biol Chem 2010; 285: 37218-37226.
22. Jin Z, Mei W, Strack S, Jia J, Yang J. The antagonistic action of B56-containing protein phosphatase 2As and casein kinase 2 controls the phosphorylation and Gli turnover function of Daz interacting protein 1. J Biol Chem 2011; 286: 36171-36179.
23. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-414. (Pubitemid 351622014)
24. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441: 518-522. (Pubitemid 44050154)
25. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-482. (Pubitemid 44050144)
26. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasomemediated degradation. J Biol Chem 2001; 276: 993-998. (Pubitemid 32096519)
27. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 2005; 280: 35195-35202. (Pubitemid 41532706)
28. Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2010; 51: 37-49.
29. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005; 12: 668-677. (Pubitemid 40767169)
30. Di Maira G, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci 2009; 66: 3363-3373.
31. Cures A, House C, Kanei-Ishii C, Kemp B, Ramsay RG. Constitutive c-Myb aminoterminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle. Oncogene 2001; 20: 1784-1792. (Pubitemid 32368024)
32. Lodie TA, Reiner M, Coniglio S, Viglianti G, Fenton MJ. Both PU.1 and nuclear factor-kappa B mediate lipopolysaccharide-induced HIV-1 long terminal repeat transcription in macrophages. J Immunol 1998; 161: 268-276. (Pubitemid 28285532)
33. Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009; 29: 2483-2488.
34. Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem 2008; 316: 149-154.
35. Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J 1996; 15: 5160-5166. (Pubitemid 26336198)
36. Shirai A, Klinman DM. The genetic basis of autoimmune disease in MRL-lpr/lpr mice. Int Rev Immunol 1994; 11: 179-192. (Pubitemid 2103927)
37. Rifkin IR, Channavajhala PL, Kiefer HL, Carmack AJ, Landesman-Bollag E, Beaudette BC et al. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha. J Immunol 1998; 161: 5164-5170. (Pubitemid 28519073)
38. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 1998; 16: 2965-2974. (Pubitemid 28297717)
39. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002; 21: 5280-5288. (Pubitemid 34948139)
40. Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N et al. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003; 22: 8255-8262. (Pubitemid 37485518)
41. Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 2007; 21: 178-180. (Pubitemid 44921853)
42. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762-3774.
43. Silva A, Jotta PY, Silveira AB, Ribeiro D, Brandalise SR, Yunes JA et al. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2-and gamma-secretase inhibitors. Haematologica 2009; 95: 674-678.
44. Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010; 116: 2513-2521.
45. Martins LR, Lucio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724-2731.
46. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288-10298.
47. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698-1707. (Pubitemid 44316140)
48. Ge F, Xiao CL, Bi LJ, Tao SC, Xiong S, Yin XF et al. Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS One 2010; 5: 1-11.
49. Phan-Dinh-Tuy F, Henry J, Boucheix C, Perrot JY, Rosenfeld C, Kahn A. Protein kinases in human leukemic cells. Am J Hematol 1985; 19: 209-218. (Pubitemid 15033402)
50. Roig J, Krehan A, Colomer D, Pyerin W, Itarte E, Plana M. Multiple forms of protein kinase CK2 present in leukemic cells: in vitro study of its origin by proteolysis. Mol Cell Biochem 1999; 191: 229-234. (Pubitemid 29092731)
51. Heriche JK, Chambaz EM. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases. Oncogene 1998; 17: 13-18. (Pubitemid 28360524)
52. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007; 13: 1019-1028.
53. Cheong JW, Min YH, Eom JI, Kim SJ, Jeung HK, Kim JS. Inhibition of CK2\{alpha\} and PI3K/Akt synergistically induces apoptosis of CD34+CD38-leukaemia cells while spari. Anticancer Res 2010; 30: 4625-4634.
54. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 2011; 118: 156-166.
55. Ljubimov AV, Caballero S, Aoki AM, Pinna LA, Grant MB, Castellon R. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 2004; 45: 4583-4591. (Pubitemid 39564687)
56. Kramerov AA, Saghizadeh M, Pan H, Kabosova A, Montenarh M, Ahmed K et al. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol 2006; 168: 1722-1736.
57. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2009; 1804: 499-504.
58. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007; 130: 986-988. (Pubitemid 47422308)
59. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA et al. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 2007; 26: 6915-6926. (Pubitemid 47609076)
60. Ruzzene M, Tosoni K, Zanin S, Cesaro L, Pinna LA. Protein kinase CK2 accumulation in 'oncophilic' cells: causes and effects. Mol Cell Biochem 2011; 356: 5-10.